Results 71 to 80 of about 73,942 (286)

Lamina Propria Phagocyte Profiling Reveals Targetable Signaling Pathways in Refractory Inflammatory Bowel Disease

Gastro Hep Advances, 2022
Background and Aims: Lamina propria phagocytes are key mediators of inflammatory bowel disease (IBD). We aimed to understand the transcriptomic and functional differences in these cells based on location, disease type, inflammation state, and medication ...
Gillian E. Jacobsen, Irina Fernández, Maria A. Quintero, Ana M. Santander, Judith Pignac-Kobinger, Oriana M. Damas, Amar R. Deshpande, David H. Kerman, Yuguang Ban, Zhen Gao, Tiago C. Silva, Lily Wang, Ashley H. Beecham, Jacob L. McCauley, Juan F. Burgueño, Maria T. Abreu   +15 more
doaj   +1 more source

Naphthyl ketones: A new class of Janus kinase 3 inhibitors

, 2000
Potent inhibition of Janus kinase 3 was found for a series of naphthyl(β-aminoethyl)ketones (e.g. 7, pIC50 = 7.1 ± 0.3). Further studies indicated that these compounds fragment in less than 1 h by retro-Michael reaction in the Jak3 in vitro ELISA assay ...
Tang, Eric, Bowyer, Jonathan, Torr, Vanessa, James, Daniel S., Rankine, Neil, Bamford, Andrea M., Culbert, Eric J., Brown, George R.   +7 more
core   +1 more source

Single‐Incision Laparoscopy‐First Strategy in Crohn's Disease: Risk Factors for Conversion and Surgical Outcomes

Annals of Gastroenterological Surgery, EarlyView.
In this retrospective study of 289 patients with Crohn's disease undergoing a single‐incision laparoscopy‐first (SILS‐first) strategy, conversion to open surgery was required in only 11.8% of cases. Fistula formation, colon resection, and smoking history were identified as independent risk factors for conversion, while postoperative complications and ...
Yuki Horio, Motoi Uchino, Yusuke Tomoo, Kentaro Nagano, Kurando Kusunoki, Ryuichi Kuwahara, Kei Kimura, Kozo Kataoka, Masataka Ikeda, Hiroki Ikeuchi   +9 more
wiley   +1 more source

Real-world patient characteristics and clinical outcomes in patients with myelofibrosis in Japan.

PLoS ONE
Anemia is associated with increased morbidity, mortality, healthcare resource utilization, and costs in myelofibrosis. This longitudinal, retrospective, and descriptive cohort study used a Japanese health administrative database (Medical Data Vision) to ...
Yusuke Yasutomi, Masashi Takano, Yi-Chen Chen, Chi-Chang Chen, Seok-Won Kim, Catherine McGuiness, Alex Slowley, Keita Kirito   +7 more
doaj   +1 more source

Novel Role of Janus Kinase 1 in the Regulation of Oncostatin M Receptor Surface Expression [PDF]

Journal of Biological Chemistry, 2002
The oncostatin M receptor (OSMR) is part of a heterodimeric receptor complex that mediates signal transduction of the pleiotropic cytokine OSM via a signaling pathway involving Janus kinases (Jaks) and transcription factors of the signal transducers and activators of transcription (STAT) family.
Radtke, Simone, Hermanns, Heike M., Haan, Claude, Schmitz-Van de Leur, Hildegard, Gascan, Hugues, Heinrich, Peter, Behrmann, Iris   +6 more
openaire   +4 more sources

Therapeutic Outcomes in VEXAS Syndrome: A Multicenter Comparative Cohort of Allogeneic Hematopoietic Stem Cell Transplantation and Hypomethylating Agents

American Journal of Hematology, EarlyView.
ABSTRACT Hypomethylating agents (HMA) and allogeneic hematopoietic stem cell transplantation (alloHSCT) have both demonstrated remissions in VEXAS; however, comparative data is lacking. We conducted a multicenter, retrospective analysis of 66 patients diagnosed with VEXAS syndrome treated with HMA (n = 35) or alloHSCT (n = 31). Baseline characteristics
Saubia Fathima, Margaret Mei‐Kay Wong, Jesus Gonzalez‐Lugo, Susan M. Geyer, Ali Alsugair, Maria Sirenko, Kimberly J. Langer, Terra L. Lasho, Christy Finke, Jun Choi, Maher Abdul‐Hay, Gary Ho, Mark R. Litzow, Aasiya Matin, Urshila Durani, Mehrdad Hefazi, William J. Hogan, Mithun V. Shah, Aref Al‐Kali, Kebede H. Begna, Naseema Gangat, Antoine N. Saliba, Ronald S. Go, Tariq Kewan, Gabriel Bartoo, Jade Kutzke, Kristen McCullough, Kenneth J. Warrington, Megan Sullivan, Kaaren K. Reichard, Horatiu Olteanu, Hemant Murthy, Talha Badar, Yael Kusne, Jeanne Palmer, Saurabh Chhabra, Nathan Punwani, Mary Riwes, Joseph P. McGuirk, Elizabeth F. Krakow, Amelia Langston, Taxiarchis Kourelis, David Dingli, James Foran, Matthew J. Koster, Mrinal M. Patnaik, David B. Beck, Hassan B. Alkhateeb, Abhishek A. Mangaonkar   +48 more
wiley   +1 more source

Use of systemic Janus-kinase inhibitors for dermatological indications in the elderly – A retrospective study of 67 cases

, 2023
Supplementary data for the research letter entitled, "Use of systemic Janus-kinase inhibitors for dermatological indications in the elderly – A retrospective study of 67 cases"THIS DATASET IS ARCHIVED AT DANS/EASY, BUT NOT ACCESSIBLE HERE.
Hren, M (via Mendeley Data)
core   +1 more source

Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week‐24 Results of a Phase 3, Randomized, Placebo‐Controlled Study

Arthritis &Rheumatology, EarlyView.
Objective To evaluate the efficacy and safety of guselkumab, an interleukin‐23p19 subunit inhibitor, in participants with active psoriatic arthritis (PsA) and inadequate response (inadequate efficacy and/or intolerance) to one prior tumor necrosis factor (TNF) inhibitor.
Alexis Ogdie, Joseph F. Merola, Philip J. Mease, Christopher T. Ritchlin, Jose U. Scher, Kimberly Parnell Lafferty, Daphne Chan, Soumya D. Chakravarty, Wayne Langholff, Yanli Wang, Jie Shao, Yevgeniy Krol, Alice B. Gottlieb   +12 more
wiley   +1 more source

From Interferon Signature to the Clinical Landscape: Type I Interferonopathies

Arthritis &Rheumatology, Accepted Article.
Background Type I interferonopathies are heterogeneous diseases driven by dysregulated IFN‐I signaling. Diagnosis is challenging due to clinical/molecular variability and the need for IFN‐I quantification. Objective To characterize the clinical, immunological, genetic, molecular profiles of patients with suspected enhanced IFN‐I signaling, and assess ...
Ismail Yaz, Seza Ozen, Hacer N. Bildik, Canberk Ipsir, Dilara Unal, Saliha Esenboga, Begum Cicek, Mehmet E. Seker, Fatima Aerts‐Kaya, Seher Sener, Mehmet O. Erkan, Hanife Avci, Deniz Cagdas, Ilhan Tezcan   +13 more
wiley   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source